Development and Characterization of Lyophilized Chondroitin Sulfate-Loaded Solid Lipid Nanoparticles: Encapsulation Efficiency and Stability
This study explores the development and characterization of lyophilized chondroitin sulfate (CHON)-loaded solid lipid nanoparticles (SLN) as an innovative platform for advanced drug delivery. <b>Background/Objectives:</b> Solid lipid nanoparticles are increasingly recognized for their biocompatibility, their ability to encapsulate diverse compounds, their capacity to enhance drug stability, their bioavailability, and their therapeutic efficacy. <b>Methods:</b> CHON, a naturally occurring glycosaminoglycan with anti-inflammatory and regenerative properties, was integrated into SLN formulations using the hot microemulsion technique. Two formulations (SLN-1 and SLN-2) were produced and optimized by evaluating critical physicochemical properties such as particle size, zeta potential, encapsulation efficiency (EE%), and stability. The lyophilization process, with the addition of various cryoprotectants, revealed trehalose to be the most effective agent in maintaining nanoparticle integrity and functional properties. <b>Results:</b> Morphological analyses using transmission electron microscopy (TEM) and atomic force microscopy (AFM) confirmed the dimensions of the nanoscales and their structural uniformity. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) revealed minimal excipient interaction with CHON, ensuring formulation stability. Stability studies under different environmental conditions highlighted that SLN-2 is the most stable formulation, maintaining superior encapsulation efficiency (≥88%) and particle size consistency over time. <b>Conclusions:</b> These findings underscore the potential of CHON-loaded SLNs as promising candidates for targeted, sustained-release therapies in the treatment of inflammatory and degenerative diseases.
Authors
- Anna Nardi-Ricart (ORCID: https://orcid.org/0000-0001-9548-3903)
- Rafel Prohens (ORCID: https://orcid.org/0000-0003-0294-1720)
- Ana Cristina Calpena (ORCID: https://orcid.org/0000-0002-4989-4821)
- Montserrat Miñarro Carmona (ORCID: https://orcid.org/0000-0002-6795-2685)
- Marta E. Bustos Araya (ORCID: https://orcid.org/0000-0001-9482-7727)
Institutions
- Universidad de Costa Rica (CR)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Institut de Nanociència i Nanotecnologia de la Universitat de Barcelona
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2025-01-10
- DOI
- https://doi.org/10.3390/pharmaceutics17010086
- Citations
- 3
- Primary Topic
- Advancements in Transdermal Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 2.37
Funders
- Universitat de Barcelona